Psoriasis: Mechanisms and entry points for possible therapeutic interventions

Australasian Journal of Dermatology

Volumn 37, Issue SUPPL. 1, 1996, Pages

  Christophers, Enno ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cyclosporin; FK 506; Psoriasis treatment protocol

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

CLINICAL TRIAL; HUMAN; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PROGNOSIS; PSORIASIS; REVIEW;

CLINICAL TRIALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOCHEMOTHERAPY; PROGNOSIS; PSORIASIS; TACROLIMUS;

EID: 0002487411     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.1996.tb01080.x     Document Type: Article

References (27)

1. Christophers E, Sterry W. Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg JM, Austen KF (eds). Dermatology in General Medicine 4th edn. New York: McGraw-Hill, 1993; 489-514.
2. Lomholt G (ed.) Psoriasis. Prevalence, Spontaneous Course and Genetics. A Census Study on the Prevalence of Skin Diseases on the Faroe Islands. Copenhagen: Gad, 1963.
3. Andressen C, Henseler T. Erblichkeit der Psoriasis. Eine Analyse von 2035 Familienanamnesen. Hautarzt 1982; 33: 214-17.
4. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch. Dermatol. 1974; 109: 207-11.
5. Branderup F, Holm N, Grunnet N et al. Psoriasis in monozygotic twins: Variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. 1982; 62: 229-36.
6. Tomfohrde J, Silverman A, Barnes R et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 1994; 264: 1141-5.
7. Nair RP, Sun-Wei Guo, Jenisch S et al. Scanning chromosome 17 for psoriasis susceptibility: No evidence for a distal 17q locus. Human Genetics (in press).
8. Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 1985; 13: 450-6.
9. Christophers E, Henseler T. Psoriasis Types I and II as subtypes of nonpustular psoriasis. Sem. Dermatol. 1992; 11: 261-6.
10. Schmidt-Egenolf M, Boehncke W-H, Ständer M, Eiermann TH, Sterry W. Oligonucleotide typing reveals association of type 1 psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. J. Invest. Derm. 1993; 100: 749-52.
11. Ellis CH, Gorsulowsky DC, Hamilton TA et al. Cyclosporin improves psoriasis in a double-blind study. J. Am. Med. Assoc. 1986; 256: 3110-16.
12. Griffiths CEM, Powles AV, Leonard JN et al. Clearance of psoriasis with low dose cyclosporin. Br. J. Dermatol. 1986; 293: 731-2.
13. Va Joost TH, Heule F, Stolz E et al. Short term use of cyclosporin A in severe psoriasis. Br. J. Dermatol. 1986; 114: 615-20.
14. Christophers E, Mrowietz U, Henneicke H-H, Färber L, Welzel D, participants in the German multicenter study. Cyclosporin in psoriasis: A multicenter dose-finding study in severe plaque psoriasis. J. Am. Acad. Dermatol. 1992; 26: 86-90.
15. Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320.
16. Nicolas JF, Chamchick N, Thivolet J et al. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321.
17. Eedy DJ, Burrows D, Bridges JM, Jones FGC. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 1990; 300: 908.
18. Gardembas-Pain M, Ifrah N, Foussard C et al. Psoriasis after allogeneic bone marrow transplantation. Arch. Dermatol. 1990; 126: 1523.
19. Gottlieb AB. Immunologic mechanisms in psoriasis. J. Invest. Dermatol. 1990; 95: S18-19.
20. + (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J. Invest. Dermatol. 1990; 95: 275-82.
21. Griffiths TW, Griffiths CEM, Voorhees JJ. Immunopathogenesis and immunotherapy of psoriasis. Dermatol. Clinics 1995; 13: 739-49.
22. Schröder JM. In: Baggiolini M, Sorg C (eds). Interleukin-8 (NAP-1) and Related Chemotactic Cytokines. Basel: Karger, 1992; 54.
23. Henseler T, Christophers E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 1995; 32: 982-6.
24. Felder R, Strömer K. Nickel sensitivity in atopics, psoriatics and healthy subjects. Contact Dermatitis 1993; 29: 65-9.
25. Vallat VP, Gilleaudeau P, Battat L et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J. Exp. Med. 1994; 180: 283-96.
26. Barker BS, Swain AF, Griffiths CEM, Leonard JN, Fry L, Valdimarsson H. Epidermal T lymphocytes and dentritic cells in chronic plaque psoriasis: The effects of PUVA treatment. Clin. Exp. Immunol. 1985; 61: 526-34.
27. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1995; 1: 442-7.